Jonathan Hollick

Jon Hollick is a seasoned professional in the pharmaceutical industry, currently serving as Managing Director and Head of Research at Breakpoint Therapeutics GmbH since July 2019. Jon co-founded the company as a spin-off of Evotec SE, focusing on the discovery of anti-cancer drugs that target the DNA Damage Response in cancer cells. Prior to this role, Jon held various positions at Evotec from February 2011 to June 2019, including Project Leader and Team Leader in Medicinal Chemistry, where leadership in drug discovery alliances and the development of an internal oncology DNA repair portfolio were key achievements. Earlier in the career, Jon gained valuable experience at Cyclacel Limited, worked as a Post-doctoral Research Fellow at the University of St Andrews and University of Dundee, and completed a PhD in Medicinal Chemistry at Newcastle University. Educational credentials also include participation in the SIU360 Bio-Entrepreneurship Programme at the Saïd Business School, University of Oxford.